In a landmark move, the National Health Service England (NHS) has become the first health system in the world to roll out a revolutionary ‘Trojan Horse’ therapy for blood cancer. The new treatment, ‘belantamab mafodotin’, is set to transform care for people living with myeloma — an incurable form of blood cancer that affects plasma cells in the bone marrow.
The therapy works by binding a powerful chemotherapy drug to an antibody, allowing it to home in on cancer cells and deliver a toxic hit from within — a method likened to the fabled wooden horse used during the siege of Troy.
For 60-year-old Paul Silvester from Sheffield, the impact has been nothing short of “life-changing”. Diagnosed nearly two years ago after cancer weakened his spine, Paul received a bone marrow transplant, but relapsed late last year. He was offered the new treatment through an early access scheme at Royal Hallamshire Hospital and was in remission within weeks. “This therapy is absolutely life-changing,” Paul told the media. “It’s creating that opportunity to enjoy life.”
Instead of months spent isolated in his bedroom — the reality with many other treatments — Paul is now planning adventures with his family. A history enthusiast, he’s preparing to visit Hadrian’s Wall and is looking forward to his daughter’s graduation. “Most people say ‘you look really, really well’… I have a good normal life,” he said.
The treatment is delivered via infusion and is significantly gentler on the body than traditional chemotherapy, though not entirely without side effects. Some patients may experience dry eyes or blurred vision as leftover chemotherapy drugs leak into the body.
Still, the benefits are substantial. Clinical trials show the therapy can hold off cancer for up to three years — nearly triple the 13-month average with current therapies. “This is a really important development,” said Prof Peter Johnson, National Clinical Director for Cancer at NHS England. “Giving patients time free of the disease and free of the symptoms is really important.”
Developed by GSK in the UK, with early research in Stevenage and trials in London, the therapy has been praised as a game-changer by researchers and charities alike. “These are very smart drugs,” said Prof Martin Kaiser of the Institute of Cancer Research. “The difference in side effects is really remarkable.” Shelagh McKinlay of Myeloma UK added: “It’s fantastic to see the UK at the forefront of myeloma treatment.”
With about 1,500 patients expected to benefit each year, the therapy marks a powerful step forward in making blood cancer treatment more targeted, effective, and humane.
